Dr. Abida on next steps with PARP inhibitors in prostate cancer

Wassim Abida, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses what the next steps should be with PARP inhibitors in prostate cancer. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer, and other PARP agents are moving through the pipeline.

Related Videos
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Dr. Adam Murphy in an interview with Urology Times
Expert cardiologist
Expert urologist
Expert cardiologist
Expert urologist
Patient predictors of postprostatectomy incontinence | Image credit: © jakkapan - stock.adobe.com
Ricardo M. de Oliveira Soares, MD, answers a question during a Zoom video interview
Expert urologist
Related Content
© 2023 MJH Life Sciences

All rights reserved.